iifl-logo-icon 1

Sun Pharmaceuticals Industries Ltd Share Price

1,593
(1.00%)
Jul 15, 2024|12:34:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,579.95
  • Day's High1,593.3
  • 52 Wk High1,638.85
  • Prev. Close1,577.3
  • Day's Low1,577.3
  • 52 Wk Low1,063.85
  • Turnover (lac)6,239.36
  • P/E124.08
  • Face Value1
  • Book Value98.75
  • EPS12.72
  • Mkt. Cap (Cr.)3,82,214.06
  • Div. Yield0.86
Loading...
  • Open1,582.75
  • Day's High1,594.7
  • Spot1,591.5
  • Prev. Close1,576.7
  • Day's Low1,581.7
  • ViewShort Covering
  • Market Lot350
  • OI(Chg %)-29,750 (-0.18%)
  • Roll Over%0.1
  • Roll Cost1.18
  • Traded Vol.9,90,850 (-69.81%)
View More Futures

Sun Pharmaceuticals Industries Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,579.95

Prev. Close

1,577.3

Turnover(Lac.)

6,239.36

Day's High

1,593.3

Day's Low

1,577.3

52 Week's High

1,638.85

52 Week's Low

1,063.85

Book Value

98.75

Face Value

1

Mkt Cap (₹ Cr.)

3,82,214.06

P/E

124.08

EPS

12.72

Divi. Yield

0.86

Sun Pharmaceuticals Industries Ltd Corporate Action

7 Jul 2023

12:00 AM

AGM

Announcement Date: 07 Jul, 2023

arrow

22 May 2024

12:00 AM

Dividend

Dividend Amount: 5

Record Date: 12 Jul, 2024

arrow

13 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Sun Pharmaceuticals Industries Ltd NEWS AND UPDATE

USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|12:11 PM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sun Pharmaceuticals Industries Ltd SHAREHOLDING SNAPSHOT

15 Jul, 2024|12:53 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 54.47%

Foreign: 0.00%

Indian: 54.47%

Non-Promoter- 36.55%

Institutions: 36.54%

Non-Institutions: 8.97%

Custodian: 0.00%

Share Price

Sun Pharmaceuticals Industries Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

239.93

239.93

239.93

239.93

Preference Capital

0

0

0

0

Reserves

23,454.47

23,508.43

24,348.02

26,698.54

Net Worth

23,694.4

23,748.36

24,587.95

26,938.47

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

15,585.98

14,116.05

12,531.93

7,923.84

yoy growth (%)

10.41

12.64

58.15

3.12

Raw materials

-5,650.39

-5,107.48

-4,567.72

-3,492.77

As % of sales

36.25

36.18

36.44

44.07

Employee costs

-2,000.78

-1,805.98

-1,702.77

-1,617.69

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

2,127.39

945.13

3,253

430.52

Depreciation

-1,349.95

-1,236.43

-561.56

-432.23

Tax paid

-406.85

-13.17

-41.86

25.39

Working capital

-5,179.41

-888.49

3,200.15

1,619.85

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

10.41

12.64

58.15

3.12

Op profit growth

28.82

-16.76

2,104.23

7.94

EBIT growth

107.43

-66.87

347.1

296.01

Net profit growth

-111.86

-73.76

-749.25

2,065.45

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

47,758.45

43,278.87

38,426.42

33,233.08

32,325.17

Excise Duty

0

0

0

0

0

Net Sales

47,758.45

43,278.87

38,426.42

33,233.08

32,325.17

Other Operating Income

738.4

606.81

228.07

265.06

512.33

Other Income

1,354.19

634.52

921.51

835.52

635.98

Sun Pharmaceuticals Industries Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,577.3

124.083,78,675.04867.60.865,536.9998.75

Cipla Ltd

CIPLA

1,512.05

32.871,22,092.681,038.40.563,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,539.3

76.441,20,480.265310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,175.15

34.281,18,217.41,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,719.45

26.171,12,137.091,034.80.595,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Sun Pharmaceuticals Industries Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

Dilip S Shanghvi

Non-Exec & Non-Independent Dir

Sudhir V Valia

Non-Exec. & Independent Dir.

Gautam Doshi

Lead Independent Director

Pawan Goenka

Independent Director

Rama Bijapurkar

Company Sec. & Compli. Officer

Anoop Deshpande

Independent Director

Sanjay K Asher

Independent Director

Rolf Hoffmann

Whole Time Director

Aalok Shanghvi

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Reports by Sun Pharmaceuticals Industries Ltd

Summary

Sun Pharmaceutical Industries Limited including its subsidiaries and associates (Sun Pharma) is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.The company has global presence with 43 manufacturing facilities across the world. India and the US are two predominant markets, accounting for nearly 70% of the companys revenue. The company has a robust product pipeline and established presence in Europe and high-growth emerging markets like Russia, Romania, South Africa, Brazil a
Read More

Company FAQs

What is the Sun Pharmaceuticals Industries Ltd share price today?

Down Arrow

The Sun Pharmaceuticals Industries Ltd shares price on N/A is Rs.₹1593.8 today.

What is the Market Cap of Sun Pharmaceuticals Industries Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceuticals Industries Ltd is ₹382406.01 Cr. as of 15 Jul ‘24

What is the PE and PB ratio of Sun Pharmaceuticals Industries Ltd?

Down Arrow

The PE and PB ratios of Sun Pharmaceuticals Industries Ltd is 124.08 and 15.98 as of 15 Jul ‘24

What is the 52 Week High and Low of Sun Pharmaceuticals Industries Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Sun Pharmaceuticals Industries Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sun Pharmaceuticals Industries Ltd is ₹1063.8 and ₹1638.7 as of 15 Jul ‘24

What is the CAGR of Sun Pharmaceuticals Industries Ltd?

Down Arrow

Sun Pharmaceuticals Industries Ltd's CAGR for 5 Years at 31.09%, 3 Years at 33.13%, 1 Year at 46.45%, 6 Month at 19.13%, 3 Month at 2.51% and 1 Month at 4.81%.

What is the shareholding pattern of Sun Pharmaceuticals Industries Ltd?

Down Arrow

The shareholding pattern of Sun Pharmaceuticals Industries Ltd is as follows:
Promoters - 54.48 %
Institutions - 36.55 %
Public - 8.97 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.